SALEM, N.H.--(BUSINESS WIRE)--Spurred by provisions of the Affordable Care Act (ACA) and other legislation, usage of breast cancer screening mammography and related follow-on diagnostic testing is expected to increase in the coming years. Yet there is wide variation in the utilization and sequence of follow-on testing on a patient-by-patient basis, including a high rate of “false positive” for biopsies (the portion of biopsies for which cancer is not detected), which suggests that better methods for selecting suspicious lesions could reduce the number of unnecessary biopsies. Efforts by payers to ensure high quality and efficient care during the screening mammogram process should therefore extend to the tests used when those mammograms return suspicious results. This is according to a new study released today that analyzes commercial claims data, prepared by Milliman, Inc. and sponsored by Gamma Medica.
Help employers find you! Check out all the jobs and post your resume.
